Welcome to our dedicated page for Rhythm Pharmaceu news (Ticker: RYTM), a resource for investors and traders seeking the latest updates and insights on Rhythm Pharmaceu stock.
Rhythm Pharmaceuticals (RYTM) is a commercial-stage biopharmaceutical company pioneering precision medicines for rare neuroendocrine diseases, including genetic obesity disorders. This page aggregates all official announcements, press releases, and verified news coverage related to RYTM's therapeutic advancements and operational developments.
Investors and stakeholders will find timely updates on regulatory milestones, clinical trial outcomes, financial disclosures, and strategic partnerships. The curated collection prioritizes primary-source materials including FDA submissions, research publications, and executive communications to ensure informational accuracy.
Track RYTM's progress in developing MC4R pathway therapies like IMCIVREE® (setmelanotide), with updates spanning global approvals, research expansions, and market access initiatives. Content is organized chronologically to facilitate efficient monitoring of the company's progress in addressing rare genetic conditions.
Bookmark this page for direct access to Rhythm Pharmaceuticals' latest verified updates. For complete market analysis, combine these resources with broader sector research and regulatory filings.
Rhythm Pharmaceuticals (NASDAQ:RYTM) presented significant clinical data for two MC4R agonists - setmelanotide and bivamelagon - in treating acquired hypothalamic obesity at ENDO 2025. The Phase 2 SIGNAL trial for bivamelagon showed significant BMI reductions of up to 9.3% in the highest dose cohort. The Phase 3 TRANSCEND trial for setmelanotide demonstrated a remarkable 19.8% placebo-adjusted BMI reduction across 120 patients.
Notably, setmelanotide showed consistent efficacy across age groups and genders, with significant results even in patients using GLP-1s. Patients with prior and concomitant GLP-1 use achieved a 25.1% BMI reduction compared to 2.0% in the placebo group. In patients under 18, the treatment led to a 26.2% reduction in the 95th percentile BMI at week 52.
Rhythm Pharmaceuticals (NASDAQ:RYTM), a global biopharmaceutical company focused on rare neuroendocrine diseases, has announced the pricing of its upsized public offering of 2,058,824 shares at $85.00 per share.
The company expects to raise approximately $175 million in gross proceeds before deducting underwriting costs and other expenses. Additionally, underwriters have a 30-day option to purchase up to 308,823 additional shares at the public offering price. The offering is expected to close around July 11, 2025.
Morgan Stanley, BofA Securities, Stifel, and Wells Fargo Securities are serving as joint book-running managers, while Canaccord Genuity and Citizens Capital Markets act as lead managers for the offering.
Rhythm Pharmaceuticals (NASDAQ: RYTM), a global biopharmaceutical company focused on rare neuroendocrine diseases, has announced a proposed public offering of $150 million of its common stock. The company will also grant underwriters a 30-day option to purchase up to an additional $22.5 million of shares.
The offering will be managed by joint book-runners Morgan Stanley, BofA Securities, Stifel, and Wells Fargo Securities, with Canaccord Genuity and Citizens Capital Markets acting as lead managers. The offering will be made through a shelf registration statement on Form S-3 that became effective on March 2, 2023.
Rhythm Pharmaceuticals (NASDAQ:RYTM) announced positive Phase 2 trial results for bivamelagon, their oral MC4R agonist, in treating acquired hypothalamic obesity. The trial demonstrated statistically significant BMI reductions of -9.3% and -7.7% in 600mg and 400mg cohorts respectively at 14 weeks, compared to a 2.2% increase in the placebo group.
The drug showed comparable efficacy to setmelanotide in post-hoc analysis, with both 400mg and 600mg cohorts achieving meaningful reductions in hunger scores (-2.8 points). Safety profile aligned with MC4R agonism, with limited instances of localized hyperpigmentation. The company plans to pursue regulatory discussions with FDA and EMA for Phase 3 trial design.
Rhythm Pharmaceuticals (NASDAQ:RYTM) has scheduled a conference call and webcast for July 9, 2025, at 8:00 a.m. ET to announce topline results from their Phase 2 clinical trial. The study evaluates bivamelagon, an investigational oral melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity.
The trial represents a significant milestone as it involves a randomized, placebo-controlled study of their novel oral treatment for a rare neuroendocrine disease. The company, which focuses on transforming lives of patients with rare neuroendocrine diseases, will provide access to the webcast through their investor relations website.
Rhythm Pharmaceuticals (NASDAQ:RYTM) announced the acceptance of three late-breaking abstracts for presentation at ENDO 2025 in San Francisco. The presentations will showcase data from multiple clinical trials focused on acquired hypothalamic obesity treatments.
Key presentations include: the Phase 3 TRANSCEND trial results evaluating setmelanotide, patient experience interviews from the TRANSCEND trial, and results from a Phase 2 trial of bivamelagon, an oral MC4R agonist. The presentations will take place between July 12-15, 2025, with all materials becoming available on the company's healthcare professional website afterward.
- Adult patients (n=20) achieved -11.9% mean BMI change at 3 months, improving to -23.0% at 9 months
- Pediatric patients showed clinically meaningful BMI z-score reductions
- The drug was generally well-tolerated
Rhythm Pharmaceuticals (NASDAQ: RYTM), a global commercial-stage biopharmaceutical company specializing in rare neuroendocrine diseases, has announced its participation in three major upcoming investor conferences. The company's Chair, President and CEO David Meeker will engage in fireside chats at:
- Bank of America Securities 2025 Healthcare Conference on May 14, 2025 at 12:20 a.m. ET
- Jefferies Global Healthcare Conference on June 4, 2025 at 3:10 p.m. ET
- Goldman Sachs Annual Healthcare Conference on June 9, 2025 at 8:00 a.m. ET
All presentations will be available via webcast on the company's website for 30 days after the events.
Rhythm Pharmaceuticals (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company specializing in rare neuroendocrine diseases, has scheduled its first quarter 2025 financial results announcement for Wednesday, May 7, 2025 at 8:00 a.m. ET.
The company will host a live conference call and webcast to present the financial results and provide a corporate update. Participants are encouraged to join ten minutes before the scheduled start time. The webcast will be accessible through the Investor Relations section of Rhythm's website and will remain available for at least 30 days after the call.